TE-031の耳鼻咽喉科領域における臨床的研究

DOI

書誌事項

タイトル別名
  • CLINICAL STUDY ON TE-031 (A-56268) IN OTORHINOLARYNGOLOGY
公開日
1988
DOI
  • 10.11250/chemotherapy1953.36.supplement3_895
公開者
公益社団法人 日本化学療法学会

この論文をさがす

説明

We studied TE-031 (A-56268) for its clinical and bacteriological usefulness in otorhinolaryngology.<BR>1. 100 mg or 200 mg of TE-031 was administered orally twice daily, before or after meals.<BR>2. TE-031 was administered to 7 patients with acute tonsillitis, 2 with otitis media and 3 with paranasal sinusitis.<BR>3. Clinical efficacy in these infections was tonsillitis 100%, otitis media 100%, and paranasal sinusitis 67%. The overall efficacy rate was 91.7%.<BR>4. Bacteriologically, one strain was isolated in each case, and the bacteriological eradication rate was 91.7%.<BR>5. No adverse events or abnormal laboratory findings were observed in any patient.<BR>From the above results, we consider TE-031 to be a safe and useful drug in otorhinolaryngological infections at a dose of 100 or 200 mg twice daily.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ